| Name | Title | Contact Details |
|---|
Inflammatix, Inc. is a venture-backed startup located in the San Francisco Bay Area that is building novel diagnostics for acute infections and sepsis based on our unique immune biomarkers. Approximately $10 billion / year is spent trying to diagnose acute infections, but current technologies that focus on `finding the bug` are (1) slow and (2) effective in fewer than 30% of cases. Inflammatix has developed a statistically rigorous, extensively validated diagnostic method that `reads` the immune system. Our HostDx™ tests report clinically actionable information on the presence, type (bacterial or viral), and severity of infection in all patients. They have been extensively validated and published in top-tier medical journals. After this initial product, Inflammatix plans to develop and commercialize additional novel diagnostic tests to address significant unmet clinical needs.
Delix Therapeutics is applying modern tools of pharmaceutical development to some of natures most ancient therapies, psychedelics.
New York-based Precision Health Media (formerly Good Health Media) delivers specific health condition audiences to pharma and consumer brands.
Neova Technologies Inc. is a Abbotsford, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer